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Abstract 
Recruitment of the serine protease plasmin is central to the pathogenesis of many bacterial species, 
including Group A streptococcus (GAS), a leading cause of morbidity and mortality globally. A key process 
in invasive GAS disease is the ability to accumulate plasmin at the cell surface, however the role of host 
activators of plasminogen in this process is poorly understood. Here, we demonstrate for the first time 
that the urokinase-type plasminogen activator (uPA) contributes to plasmin recruitment and subsequent 
invasive disease initiation in vivo. In the absence of a source of host plasminogen activators, 
streptokinase (Ska) was required to facilitate cell surface plasmin acquisition by GAS. However, in the 
absence of Ska, host activators were sufficient to promote cell surface plasmin acquisition by GAS strain 
5448 during incubation with plasminogen or human plasma. Furthermore, GAS were able mediate a 
significant increase in the activation of zymogen pro-uPA in human plasma. In order to assess the 
contribution of uPA to invasive GAS disease, a previously undescribed transgenic mouse model of 
infection was employed. Both C57/black 6J, and AlbPLG1 mice expressing the human plasminogen 
transgene, were significantly more susceptible to invasive GAS disease than uPA−/− mice. The observed 
decrease in virulence in uPA−/−mice was found to correlate directly with a decrease in bacterial 
dissemination and reduced cell surface plasmin accumulation by GAS. These findings have significant 
implications for our understanding of GAS pathogenesis, and research aimed at therapeutic targeting of 
plasminogen activation in invasive bacterial infections. 
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Abstract
Recruitment of the serine protease plasmin is central to the pathogenesis of many bacterial species, including Group A
streptococcus (GAS), a leading cause of morbidity and mortality globally. A key process in invasive GAS disease is the ability
to accumulate plasmin at the cell surface, however the role of host activators of plasminogen in this process is poorly
understood. Here, we demonstrate for the first time that the urokinase-type plasminogen activator (uPA) contributes to
plasmin recruitment and subsequent invasive disease initiation in vivo. In the absence of a source of host plasminogen
activators, streptokinase (Ska) was required to facilitate cell surface plasmin acquisition by GAS. However, in the absence of
Ska, host activators were sufficient to promote cell surface plasmin acquisition by GAS strain 5448 during incubation with
plasminogen or human plasma. Furthermore, GAS were able mediate a significant increase in the activation of zymogen
pro-uPA in human plasma. In order to assess the contribution of uPA to invasive GAS disease, a previously undescribed
transgenic mouse model of infection was employed. Both C57/black 6J, and AlbPLG1 mice expressing the human
plasminogen transgene, were significantly more susceptible to invasive GAS disease than uPA2/2 mice. The observed
decrease in virulence in uPA2/2mice was found to correlate directly with a decrease in bacterial dissemination and reduced
cell surface plasmin accumulation by GAS. These findings have significant implications for our understanding of GAS
pathogenesis, and research aimed at therapeutic targeting of plasminogen activation in invasive bacterial infections.
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Introduction
An emerging theme in bacterial pathogenesis is sequestration of
host plasminogen during disease initiation [1]. This has inspired
research to develop therapeutic inhibitors of bacterial plasminogen
activation and recruitment [2,3,4,5]. To be successful, such
strategies require a comprehensive understanding of how bacteria
interact with the host fibrinolytic system. Group A streptococcus
(GAS) is a globally significant human pathogen, responsible for
600,000 cases of invasive infection each year, approximately 25%
of which are fatal [6]. The ability of GAS to accumulate cell
surface plasmin activity is an essential step in the initiation of
invasive disease [7,8], but the mechanistic basis of this virulence
property has yet to be fully elucidated. While in vitro analyses
suggest a role for host plasminogen activators in GAS disease
[9,10,11], this hypothesis has yet to be conclusively demonstrated
in vivo.
The glycoprotein plasminogen is found in plasma and
extracellular fluids at concentrations of approximately 2 mM.
Activation of plasminogen leads to the generation of the serine
protease plasmin. Plasmin is able to degrade fibrin clots,
connective tissue, extracellular matrix (ECM) and adhesion
proteins. Additionally, activation of pro-metalloproteases by
plasmin results in degradation of the collagen structural compo-
nents of the ECM, leading to widespread tissue destruction [12].
Conversion of plasminogen to plasmin can be facilitated by both
host and bacterial activators. The major circulating inhibitor of
plasmin is a2-antiplasmin. However, surface bound plasmin is less
susceptible to inactivation by a2-antiplasmin [13]. GAS secrete the
plasminogen activator streptokinase (Ska), which is highly specific
for human plasminogen [14]. The contribution of Ska to GAS
virulence is well established, however previous studies have shown
that deletion of ska from the GAS chromosome significantly, but
not completely, attenuates GAS virulence [9,10,11]. This implies a
role for host activators. There are two distinct eukaryotic
activators of plasminogen, urokinase-type plasminogen activator
(uPA) and tissue plasminogen activator (tPA). uPA is primarily
involved in cell-associated plasminogen activation. The zymogen
pro-uPA can be activated by a variety of proteases, including
plasmin [15,16,17]. Cleavage of the inactive form of the urokinase
PLOS Pathogens | www.plospathogens.org 1 July 2013 | Volume 9 | Issue 7 | e1003469
plasminogen activator pro-uPA by cell bound plasmin generates
the active two-chain uPA. This feedback activation results in a
significant increase in plasmin activation within biological systems
[18]. uPA is localized on the surface of human cells that contribute
to epithelial and innate immune defense against bacterial
infection, including keratinocytes, neutrophils and macrophages
[19]. Furthermore, uPA is upregulated in response to bacterial
sepsis, and elevated uPA levels can be correlated to poor patient
outcome [20,21]. Here we utilise a series of isogenic GAS mutants,
in conjunction with a newly developed mouse model of infection,
to assess the role of uPA in invasive GAS disease.
Results
Host plasminogen activators are sufficient for the
acquisition of cell surface plasmin by GAS
Streptokinase, encoded by the ska gene, is a GAS activator of
human plasminogen [14]. To study streptokinase-dependent
and -independent interactions of GAS with the host plasmin-
ogen activation system, we used wild-type (WT) GAS strain
(5448) isolated from a patient with necrotizing fasciitis and
toxic shock syndrome. This strain belongs to the globally-
disseminated serotype M1T1 clone that is the leading cause of
invasive GAS infections in recent decades [22]. An isogenic
streptokinase-deficient mutant of this strain (5448Dska), which
was generated by allelic replacement of the ska gene with a
chloramphenicol acetyltransferase (cat) gene, has been de-
scribed previously [5]. This mutant was subsequently comple-
mented by reinsertion of the wild-type ska gene in place of cat
(5448*). PCR confirmed the genetic manipulations, and
western blot analysis showed that 5448Dska lacked streptoki-
nase expression whereas WT strain 5448 and complemented
strain 5448* expressed equivalent levels of the protein. The
three GAS strains grew equivalently in bacteriologic media,
expressed equivalent levels of surface hyaluronic acid capsule,
and bound equivalent amounts of plasminogen following
incubation in human plasma (Fig S1). As predicted, when
incubated in human plasma, the WT 5448 and complemented
5448* GAS strains were able to accumulate plasmin activity at
their cell surface, however, deletion of ska from the GAS
chromosome resulted in a significant, but partial attenuation in
plasmin accumulation (Fig. 1A). This suggests that endogenous
host derived plasminogen activators and plasminogen, present
in the human plasma, contribute to cell surface plasmin
acquisition by GAS. Upon incubation of GAS with human
Glu-plasminogen and active human uPA, the 5448Dska mutant
accumulated surface plasmin activity equivalent to the WT
parent strain (Fig. 1B), suggesting that host-derived uPA can
contribute to cell surface plasmin acquisition by GAS.
Similarly, GAS were able to acquire cell surface plasmin
activity in the presence of human Glu-plasminogen and human
tPA (Fig S2), supporting the hypothesis that host plasminogen
activators are mediators of plasmin acquisition by GAS [7].
GAS facilitates enhanced uPA generation in plasma
uPA is expressed as the zymogen pro-uPA, which has limited
plasminogen activating potential [23,24]. Activation of pro-uPA
occurs via plasmin mediated proteolytic cleavage of the zymogen.
Activation of pro-uPA to uPA is enhanced when the plasmin
source is localised to the cell surface, and the reciprocal activation
of pro-uPA by plasmin and hence co-localised plasminogen by
uPA is an important mechanism in the regulation of plasmin
activity [25]. Plasmin localised at the GAS cell surface, where it is
protected from a2-antiplasmin inhibition [26], may therefore
facilitate enhanced uPA activation in plasma. uPA activity levels in
plasma were monitored using the uPA specific fluorescence
substrate Z-Gly-Gly-Arg-AMC over 2 hours. The initial rate of
uPA activity was greater in plasma containing either 5448, 5448*
or 5448Dska compared with plasma alone (Fig. 2). In the presence
of 16107 colony forming units (CFU), the initial rate of pro-uPA
activation was found to be 10.6(+/20.928) fluorescence units (fu)/
min, 9.812 (+/20. 957) fu/min , and 8.635 (+/21.078) fu/min for
5448, 5448* and 5448Dska, respectively, compared with a rate of
4.921(+/20.0.215) fu/min in plasma alone. The concentration of
active uPA in plasma at t30 was determined to be 0.183 (+/
20.035) nM in the presence of 5448, 0.166 (+/20.031) nM in the
presence of 5448*, 0.144 (+/20.023) nM in the presence of
5448Dska and 0.054 (+/20.018) nM in plasma alone. These data
suggest the presence of endogenous pro-uPA in human plasma
that is readily activatable by GAS-bound plasmin.
uPA plays a central role in invasive GAS infection
Using a knockout mouse lacking uPA, we assessed the role of host
uPA in the development of invasive GAS disease. Following
intradermal infection with WT GAS strain 5448 at a high dose
(16109 colony forming units/dose), C57 black/6J mice displayed
significantly higher mortality (P = 0.04) than C57 black/6JuPA2/2
mice (Fig. 3A). Recognizing that the interaction between
streptokinase and plasminogen is species specific, and that the
presence of human plasminogen increases the severity of invasive
GAS infection in the murine model [7,8,9,11], we crossed the
humanized plasminogen mouse line AlbPLG1 with C57 black/
6JuPA2/2 mice to establish AlbPLG1/uPA2/2 infection model.
The ability of GAS to acquire cell surface plasmin activity in the
presence of human plasminogen and mouse uPA confirmed the
ability of mouse uPA to activate human plasminogen at the GAS
cell surface (Fig. 3B), and survival of mice infected intradermally
with GAS (16109 colony forming units/dose) increased signifi-
cantly in mice deficient in uPA (Fig. 3C). Deletion of uPA did not
completely eliminate virulence of GAS in this model, which may
be explained by the presence of the host plasminogen activator
tPA. As with uPA, mouse tPA will activate human plasminogen at
the GAS cell surface (Fig S2B). However, mortality was reduced
from 80% to 20% in the absence of both uPA and streptokinase
(Fig. 3C).
Author Summary
Subversion of the host fibrinolytic system by bacterial
pathogens is recognised as a key process in severe disease
initiation. Co-opting of plasmin by bacteria contributes to
tissue destruction and bacterial dissemination, both
hallmarks of invasive Group A streptococcal disease, and
research aimed at therapeutic targeting of the nexus
between group A streptococcus and the fibrinolytic
system is increasing. The host plasminogen activator uPA
is found at the surface of cells that contribute to epithelial
and innate immune defense against bacterial infection,
and may contribute to bacterial recruitment of plasmin,
however, the role of uPA in group A streptococcal
infection is not well characterised. Here, we describe for
the first time the key role played by uPA in invasive group
A streptococcal disease. The ability of this pathogen to
cause severe infection, even in the absence of the bacterial
plasminogen activator streptokinase, has significant impli-
cations for the development of therapeutics to control
invasive bacterial infection.
uPA in GAS Infection
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Loss of virulence in the AlbPLG1/uPA2/2 mouse model
correlates with decreased bacterial dissemination and a
decrease in cell surface plasmin acquisition by GAS
The ability of pathogens to sequester plasmin has been
implicated in bacterial dissemination during systemic infection
[9]. To determine if uPA mediated plasmin acquisition contributes
to GAS dissemination, we compared the ability of WT GAS strain
5448 to disseminate during infection of AlbPLG1 and AlbPLG1/
uPA2/2 mice. In comparison to AlbPLG1 mice, significantly
lower numbers of bacteria were detected in the blood (P,0.05)
and spleen (P,0.05) of AlbPLG1/uPA2/2 mice 72 h post-
infection (Fig. 4A). The number of bacteria isolated from the
subcutaneous site of infection was similar in the two mouse lines,
indicating that differences did not reflect differential ability of the
bacteria to survive at the site of infection. This was further
supported by the finding that there was no significant difference in
Figure 1. Cell surface plasmin acquisition in the absence of streptokinase. A GAS strains 5448 (black fill), 5448Dska (no fill) and 5448* (grey
fill) readily acquire cell surface plasmin activity during a 3 h incubation in human plasma, but not plasminogen-depleted plasma or PBS. B In the
absence of streptokinase, uPA can mediate cell surface plasmin acquisition by GAS in vitro. Data is representative of 2 independent experiments. Error
bars indicate SEM (n = 3), asterisks indicate statistical significance as determined by unpaired two-tailed students t-test P,0.005 (**), P,0.001 (***).
doi:10.1371/journal.ppat.1003469.g001
uPA in GAS Infection
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lesion size between AlbPLG1 and AlbPLG1/uPA2/2 mice (Fig. 4B).
GAS acquired significantly lower levels of cell surface plasmin ex
vivo in plasma from AlbPLG1/uPA2/2 compared with AlbPLG1
mice (Fig. 4C). These data clearly indicate that uPA contributes to
cell surface plasmin acquisition and bacterial dissemination in
invasive GAS disease.
Discussion
Despite increased research efforts over the past 20 years, GAS
remains a significant human pathogen, with continued outbreaks
of serious GAS infection globally [6]. Interaction with the host
protease plasmin is central to the onset of invasive GAS disease
[1]. A major consequence of plasmin acquisition in GAS infection
is to facilitate bacterial escape from fibrin networks. uPA can
facilitate efficient fibrin clearance in the absence of both uPAR
and tPA [27], and the results of the current study provide for the
first time, evidence that uPA mediated plasmin acquisition
facilitates widespread systemic infection by GAS.
GAS were able to establish a subcutaneous infection at the site
of inoculation, but showed a decreased propensity for dissemina-
tion from the site of local infection and systemic disease initiation
in the absence of uPA. This reduced virulence could be directly
correlated to reduced bacterial plasmin acquisition in plasma from
uPA2/2 mice. Previously, uPA deficiency has been linked to
impaired wound healing [27,28,29]. No significant difference was
seen 3 days post infection in lesion sizes for AlbPLG1 and AlbPLG1/
uPA2/2 mice. This may reflect the contribution of numerous
secreted GAS virulence factors to localised inflammation and
lesion development. Comparison of lesion size between AlbPLG1
and AlbPLG1/uPA2/2 mice was not performed at later time
points due to poor survival of AlbPLG1 mice following GAS
infection, however, it appears that in this model, lesion size is not
indicative of the propensity of GAS to initiate systemic disease.
The finding that virulence was not fully attenuated in the
humanised plasminogen uPA2/2 background is not unexpected,
given the well established role for streptokinase in GAS virulence,
and the presence of the other major host plasminogen activator
tPA in this model. However, GAS virulence was further
attenuated following deletion of ska, providing further evidence
of a role for co-operative plasminogen activation in GAS invasive
disease.
The contribution of streptokinase to plasminogen-dependant
GAS virulence has been well documented [9], and data presented
here clearly show that in the absence of host activators,
streptokinase is an absolute requirement for cell surface plasmin
acquisition by GAS strain 5448. However, previous studies suggest
that even in the absence of streptokinase, GAS are able to acquire
cell surface plasmin activity [9,10]. Following deletion of ska from
the chromosome, GAS strain 5448 acquired cell surface plasmin
activity in both human plasma and in the presence of plasminogen
and uPA. This study therefore demonstrates that streptokinase is
not essential for sequestration of plasmin by GAS. The ability of
GAS to access a source of plasmin in the absence of streptokinase
may have relevance at stages of infection where streptokinase
expression is downregulated, or when streptokinase is degraded by
other GAS virulence factors such as SpeB. The GAS protease
SpeB has been shown to degrade key mediators of plasminogen
acquisition, including streptokinase, but not receptors for plasmin
and plasminogen such as the streptococcal enolase [8]. uPA
mediated plasmin acquisition may therefore be critical during
early infection when SpeB is abundant [11], providing a source of
plasmin for recruitment to the cell surface. uPA can be detected in
normal human plasma and is expressed at the leading edge of
keratinocytes and macrophages during wound healing [19,30].
Additionally, uPA stored in intracellular vesicles in neutrophils is
released into the extracellular space following activation [31]. The
abundance of migrating and inflammatory cells during GAS
infection therefore represents a significant source of uPA that can
contribute to plasmin acquisition by GAS. Furthermore, receptor
bound plasmin is resistant to a2-antiplasmin inhibition, enhancing
the activation of receptor bound pro-uPA [32]. Plasmin bound to
GAS cell surface receptors may therefore further amplify uPA
mediated proteolysis. The finding in this study that GAS are able
to enhance uPA generation in plasma supports a scenario in which
plasmin localised to the GAS surface enhances activation of pro-
uPA to uPA, effectively creating an activation cascade leading to
enhanced proteolysis [18].
Upregulation of uPA in bacterial meningitis is associated with
poor patient outcome and breaching of the blood cerebrospinal
Figure 2. GAS facilitates enhanced uPA activity in plasma. Endogenous uPA activity in human plasma was measured using the uPA specific
fluorogenic substrate Z-Gly-Gly-Arg-AMC, in the presence or absence of GAS strains 5448, 5448* and 5448Dska. Data is representative of four
independent experiments, performed in duplicate. Background fluorescence has been subtracted from all values.
doi:10.1371/journal.ppat.1003469.g002
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Figure 3. uPA contributes to bacterial disease dissemination in vivo. A Cohorts of 10 age and sex matched mice were subcutaneously
infected with 16109 CFU of GAS strain 5448 or 5448Dska. C57 black/6J uPA 2/2 mice (dashed line) showed a significant increase in survival (P,0.05)
compared to C57 black/6J mice (solid line). B Mouse uPA can mediate activation of human plasminogen, and human plasmin acquisition by 5448
uPA in GAS Infection
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fluid barrier [21], and uPA is upregulated in response to numerous
bacterial infections, including bacterial sepsis [20,33]. Whilst the
ability of bacteria to degrade clots and ECM using uPA activated
plasmin has been demonstrated repeatedly in vitro (reviewed in [1]),
the contribution of uPA to GAS virulence has not been established
in vivo. We now show for the first time, that uPA mediated
plasminogen activation contributes to systemic GAS disease in vivo
using a novel model of GAS infection AlbPLG1/uPA2/2 mice.
It has been suggested that targeting the nexus between bacteria
and the fibrinolytic system to inhibit bacterial plasmin activation
may provide therapeutic benefit [2,3,4,5], and indeed, data
presented here support this proposal. However, the development
of potential therapeutics is currently hampered by our limited
understanding of this process. Clearly, inhibitors targeting
streptokinase mediated plasmin acquisition would not be sufficient
to prevent bacterial plasmin accumulation by GAS. Understand-
ing the mechanisms behind bacterial interaction with key
components of the fibrinolytic system may therefore aid in the
development of therapeutics to control GAS infection.
Materials and Methods
Ethics approvals
Permission to collect human blood was obtained from the
University of Wollongong Human Ethics Committee (HE08/250).
Blood was taken from healthy adult volunteers, who provided
informed, written consent. Animal experiments were performed
according to the Australian code of practice for the care and use of
Animals for scientific purposes, and the NIH Guide for the care
and use of laboratory animals. Permission was obtained from the
University of Wollongong (AE11/04; AE12/05) and the Univer-
sity of Notre Dame ethics committees. Volunteers provided
informed consent before blood samples were obtained.
Bacterial strains and culture conditions
GAS strains were routinely cultured in Todd-Hewitt broth
containing 1% yeast (THBY) or grown on horse blood agar (HBA)
plates at 37uC. Invasive GAS isolate 5448 has been described
previously [8,11]. A precise, in-frame allelic replacement of the ska
gene with cat encoding chloramphenicol transferase was created in
GAS wild type strain 5448 using established methods [7]. The
mutation was subsequently reversed by replacement of the cat gene
with the wildtype ska gene. The resulting strains were designated
5448Dska and 5448* respectively. Briefly, an 854 bp fragment
upstream of ska was PCR amplified with primers ska-upF (59-
TGTACCCGCAGTTACCTGATACC-39) and ska-upRcat (59-
AGAAACCTCCTACTAAAAGTTAAG-39), the latter contain-
ing a 30 bp 59 overhang homologous to the 59 end of cat. A 853 bp
fragment downstream of ska was amplified by primers ska-
downFcat (59-CCACGATCTTCTAAAATGATG-39), containing
a 30-bp 59 overhang homologous to the 39 end of cat, and ska-
downR (59-TGGCTACCAAGAACGCTTGATTG-39). The up-
stream and downstream fragments were combined with the
650 bp cat gene in a fusion PCR reaction using primers ska-upF
and ska-downR, creating an amplicon in which ska had been
precisely replaced with cat. For reversal of the mutation process,
primers ska-upF and ska-downR were used to amplify ska from the
5448 chromosome. The resulting fragments were TA cloned into
pCR-2.1-TOPO (Invitrogen) and subsequently digested with
restriction enzymes BamHI and XbaI, then ligated into the
temperature sensitive vector pHY304, to generate the knockout
plasmid pskaKO, and the restoral plasmid pHYska. Plasmids were
transformed into GAS strain 5448 or 5448Dska by electroporation.
Transformants were identified at the permissive temperature of
30uC under erythromycin (4 mg/ml) selection. Transformants
were then grown at the non-permissive temperature of 37uC with
erythromycin to select for homologous recombination and
integration of the plasmid into the genome. Single crossovers
were confirmed by PCR analysis. Release of the plasmid was
carried out at 30uC with no antibiotic selection. Screening for
erythromycin-sensitive colonies was used to identify double
crossover events and allelic replacement mutants were confirmed
by PCR and DNA sequence analysis.
Hyaluronic acid capsule assay
Overnight GAS cultures were used to inoculate fresh THBY.
Cultures were grown to an OD600 nm of 0.5–0.6. Capsule was
extracted and assayed using the Stains-All method, as described
previously [34].
Western blot analysis of streptokinase expression
GAS strains were screened for streptokinase expression via
western blot analysis as described previously [8]. Briefly, GAS
strains were cultured overnight in the presence of the SpeB
inhibitor E64 (Sigma-Aldrich). Trichloroacetic-precipitated pro-
teins from culture supernatants were assayed for the presence of
streptokinase using rabbit polyclonal streptokinase antiserum. The
antisera used and the conditions for Western blot analysis have
been described in detail elsewhere [8].
Cell surface plasminogen acquisition
GAS (16107 CFU) were incubated with 500 nM Human Glu-
Plg (Haemotologic Technologies) for 2 h at 37 degrees. Following
26 washes with PBS, plasminogen was eluted from the bacterial
cell surface using 100 mM Glycine-HCl (pH 2.0) as described
previously [7]. The eluent was screened for the presence of
plasminogen by western blot analysis using rabbit anti human
plasminogen (Calbiochem), goat anti -rabbit IgG HRP conjugate
(Invitrogen), and enhanced chemiluminescence detection.
Host activator mediated cell surface plasmin acquisition
The ability of human uPA (Calbiochem) and mouse uPA
(Molecular Innovations), or human tPA (Calbiochem) and mouse
tPA (Molecular Innovations) to mediate cell surface plasmin
acquisition by GAS in the presence of human Glu-plasminogen
(Enzyme Research) was determined using an in vitro plasminogen
acquisition assay. GAS cultures were grown to mid-log phase
(OD600 nm = 0.5), and 1610
8 cells harvested by centrifugation at
6,0006 g. Cells were washed twice by resuspension in PBS,
followed by resuspension in PBS containing Glu-plasminogen
(1 mg/ml), uPA (3 units), tPA (3 units), Glu-Plasminogen and
uPA/tPA, or PBS alone. Following incubation for 1 h at 37uC,
cells were washed twice in PBS to remove any unbound plasmin,
and resuspended in PBS. The plasmin activity of this resuspension
(black fill) and 5448Dska (no fill). C AlbPLG1/uPA 2/2 mice infected with 5448 (dashed line) or 5448Dska (dotted line) showed a significant increase in
survival (P,0.01) compared to AlbPLG1 mice infected with 5448 (solid line). Survival data is combined from two independent experiments (n = 20),
and significance was determined by log-rank test. Plasmin acquisition data is representative of two independent experiments, error bars indicate SEM
(n = 3). Asterisks indicate statistical significance as determined by unpaired two-tailed students t-test, P,0.05 (*), P,0.001 (***).
doi:10.1371/journal.ppat.1003469.g003
uPA in GAS Infection
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Figure 4. Bacterial dissemination in vivo correlates with uPA mediated plasmin acquisition. A Bacterial counts in the bloodstream and
spleen of mice were significantly higher in AlbPLG1 mice (black circles) than in AlbPLG1/uPA 2/2 mice (white circles). B AlbPLG1 and AlbPLG1/uPA 2/2
mice develop equivalent lesions 3 days post-inoculation with GAS strain 5448. C GAS strains 5448 (black fill) and 5448Dska (no fill) accumulate
significantly lower levels of cell surface plasmin ex vivo in AlbPLG1/uPA2/2 compared with AlbPLG1 plasma. Dissemination and lesion size data is
combined from 3 independent experiments (n = 6). Plasmin acquisition data is representative of two independent experiments, error bars indicate SEM
(n = 3). Asterisks indicate statistical significance as determined by unpaired two-tailed students t-test, P,0.05 (*), P,0.001.
doi:10.1371/journal.ppat.1003469.g004
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was determined using the chromogenic substrate S-2251 (2.5 mM;
Sigma-Aldrich).
Cell surface plasmin acquisition in human plasma and
mouse plasma
Cell surface plasmin activity assays were conducted following
incubation of GAS in human or mouse plasma for 3 has described
previously [7]. Plasmin activity was determined as above.
uPA activation in human plasma
uPA activity in plasma and plasma containing GAS, was
measured using the fluorogenic substrate Z-Gly-Gly-Arg-AMC
(Calbiochem). Fluorescence observed in this assay is directly
proportional to uPA activity due to the high specificity of the
substrate for uPA [35]. The excitation wavelength range of the
substrate is 365–380 nm and the emission wavelength range is
430–460 nm. GAS were prepared as described above, and
16107 CFU of bacteria added to human plasma, and trans-
ferred to a fluor plate. Samples were overlayed with an
equivalent volume of PBS containing 1 mM Z-Gly-Gly-Arg-
AMC to give a final concentration of 0.5 mM of the fluorogenic
substrate. A sample to indicate background fluorescence
containing GAS, fluorogenic substrate and buffer was included
in assay plates. Fluorescence emission was measured immedi-
ately using a Fluostar Optima instrument at 37uC (BMG
Labtech, Offenburg, Germany). Data was recorded at 3 min
intervals over a period of 120 min. The background fluores-
cence was subtracted from each reading before statistical
analysis. Calculation of the initial rate of change in fluorescence
min_1 allowed quantitative interpretation of fluorescence data
and was generated using the linear region of the graph where
fluorescence was plotted against time, over the first 30 min of
the assay. The final concentration of uPA generated under each
experimental condition was determined from standard curve
measuring relative fluorescence over time in the presence of
increasing concentrations of uPA.
Animals
AlbPLG1 mice heterozygous for the human plasminogen
transgene [9] were bred as described previously [8]. To construct
the uPA knockout lines, C57BL/J6 mice or AlbPLG1 mice were
backcrossed with or C57BL/J6upa2/2 mice, in which upa is
replaced with neo [28] .6 times. Mouse genotype was confirmed
by PCR following tail snip as described previously [9,28]
Streptococcal infection model
GAS cultures were grown to mid-log phase (OD600 nm = 0.5).
Following centrifugation, bacteria were washed twice, and
resuspended in 0.7% (w/v) saline. For survival studies, cohorts
of 10 mice were infected subcutaneously with 16109 colony
forming units of 5448, and survival was monitored over a 10-day
period. For studies investigating bacterial dissemination, mice
(n = 6) were inoculated with 46108 colony forming units of 5448.
72 h post infection, the lesion (site of infection), blood, and spleen
were collected and the number of viable bacteria determined.
Lesion size was determined as described previously [10]. In all
studies mice were aged between 6 and 12 weeks, and cohorts were
matched for age and sex. The number of CFU used for infection
was determined by serial dilution of the inoculum post-infection,
plating on horse blood agar, and colony counting following
overnight incubation at 37uC.
Statistical analysis
Survival data was analysed by log-rank test. All other data was
analysed using a two-tailed unpaired students t-test. Statistical
analysis was performed using GraphPad Prism 5.00 (GraphPad,
San Diego, CA, USA).
Supporting Information
Figure S1 Complementation of ska deletion in GAS
strain 5448. A PCR screening confirmed the replacement of ska
with cat in the 5448 chromosome (5448Dska) and subsequent
replacement of cat with ska (5448*). B Western blot analysis
confirmed the abrogation of streptokinase expression by 5448Dska.
The wildtype 5448 phenotype was successfully restored following
replacement of cat with ska (5448*). C Allelic replacement
experiments did not alter the growth characteristics of 5448 (solid
line), 5448Dska (dotted line), or 5448* (dashed line) in bacterial
culture. D Allelic replacement experiments did not alter levels of
hyaluronic acid capsule expression by GAS. E Western blot
analysis confirmed the ability of GAS strains 5448, 5448Dska, and
5448* to bind equivalent amounts of human plasminogen.
(TIFF)
Figure S2 tPA mediated cell surface plasmin acquisition
by GAS. A In the absence of streptokinase, tPA can mediate cell
surface plasmin acquisition by GAS strains 5448 (black fill),
5448Dska (no fill) and 5448* (grey fill) in vitro. B Mouse tPA can
mediate activation of human plasminogen, and human plasmin
acquisition by 5448 (black fill) and 5448Dska (no fill) and 5448*
(grey fill). Data is representative of 2 independent experiments.
Error bars indicate SEM (n = 3), asterisks indicate statistical
significance as determined by unpaired two-tailed students t-test
P,0.005 (**), P,0.001 (***).
(TIFF)
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